NMDA-gated ion channel research and its therapeutic potentials in neurodegenerative diseases: a review
Open Access
- 1 November 2009
- journal article
- review article
- Published by Taylor & Francis in Journal of Receptor, Ligand and Channel Research
- Vol. ume 2, 59-73
Abstract
NMDA-gated ion channel research and its therapeutic potentials in neurodegenerative diseases: a review Maryam Majdi1, Huei-Sheng Vincent Chen1,21Center for Neuroscience, Aging and Stem Cell Research, Burnham Institute for Medical Research, La Jolla, California, USA; 2Division of Cardiology, University of California, San Diego, San Diego, California, USA The N-methyl-D-aspartate (NMDA) subtype of glutamate receptor (NMDAR) is essential for normal function of the central nervous system (CNS). Classical NMDARs, activated by glycine and glutamate, are heteromultimers comprising NR1 and NR2 subunits. Nonetheless, excessive activation of NMDARs by excitatory amino acids such as glutamate is thought to mediate neuronal damage in many neurological disorders. The dual role of NMDARs in normal and abnormal functioning of the CNS imposes significant constraints on possible therapeutic strategies aimed at ameliorating neurodegenerative diseases. To create safe NMDAR-based therapies, blockade of excessive NMDAR activity must therefore be achieved with minimal interference on its normal neuronal function. In general, NMDAR antagonists can be classified pharmacologically according to the site of action on the receptor-channel complex. These include drugs acting at the agonist sites (NMDA and glycine), channel pore, and modulatory sites. Both competitive NMDA and glycine antagonists result in generalized inhibition of NMDAR activities and have, thus, failed in clinical trials. Open-channel blockers with uncompetitive antagonism and drugs modulating NMDAR activities are appealing therapeutic strategies because, in theory, these properties could decrease neurotoxicity due to excessive levels of glutamate while sparing physiological neurotransmission. We review here NMDAR-related research that may lead to future therapeutic intervention against neurotoxicity.Keywords: excitotoxicity, open-channel block, uncompetitive antagonism, Alzheimer disease, memantineKeywords
This publication has 101 references indexed in Scilit:
- Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonismMovement Disorders, 2008
- The N-methyl-D-aspartate antagonist memantine retards progression of Huntington’s disease2004
- NMDA receptor function in mouse models of Huntington diseaseJournal of Neuroscience Research, 2001
- Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents - toward an understanding of their favorable tolerabilityAmino Acids, 2000
- Modifications of neuronal phosphorylated τ immunoreactivity induced by NMDA toxicityMolecular and Chemical Neuropathology, 1996
- Disappearance of actin‐binding protein, drebrin, from hippocampal synapses in alzheimer's diseaseJournal of Neuroscience Research, 1996
- Age-dependent loss of NMDA receptors in hippocampus, striatum, and frontal cortex of the rat: Prevention by acetyl-l-carnitineNeurochemical Research, 1994
- Region‐specific age effects on AMPA sensitivity: Electrophysiological evidence for loss of synaptic contacts in hippocampal field CA1Hippocampus, 1992
- β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damageBrain Research, 1990
- Distribution and Metabolism of the Potential Anti-Parkinson Drng Memantine in the Human1980